Thursday’s Daily Piece: Exciting New Updates on Fiasp and Farxiga

Well, it is another exciting week in the world of diabetes. First, more rapid acting insulin aspart (Fiasp) now has expanded FDA indication for use in insulin pumps.

https://www.medscape.com/viewarticle/920162?nlid=132222_3901&src=wnl_newsalrt_191022_MSCPEDIT&uac=293412PG&impID=2139522&faf=1

Secondly, dapaglifozin (Farxiga) is now first medication indicated for treatment of Type 2 diabetes that is approved to reduce risk of heart failure hospitalization in adults with type 2 diabetes and established cardiovascular (heart) disease or multiple risk factors for heart disease. The data from the Dapagliflozin Effect on Cardiovascular Events-TIMI 58 (DECLARE-TIMI 58) trial led to this new approved indication. Please do keep in mind that in general the SGLT2 inhibitor drug class (class effect) has shown benefit for persons with type 2 diabetes and heart failure.

https://www.medpagetoday.com/cardiology/chf/82845?xid=nl_mpt_SREndocrinology_2019-10-22&eun=g1137305d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=EndoUpdate_102219&utm_term=NL_Spec_Endocrinology_Update_Active

https://univadis.com/player/yqzsqyhmi/alist_nlts_1571907600727?m=unv_eml_essentials_enl_v5-q3-2019-newsrndm_20191024&partner=unl&rgid=5xzzntsmvumvuucxuzefqyb&ts=2019102400&o=tile_1_id&utm_source=Retention&utm_medium=newsletter&utm_campaign=unv_eml_essentials_enl_v5-q3-2019-newsrndm_20191024_01

Please share your thoughts and subscribe to receive my blogs.

#Fiasp #FDA #Farxiga #HF

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.